ATI 0917

Drug Profile

ATI 0917

Alternative Names: ATI-0917; FB 636

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Developer Arisyn Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action HIV replication inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in USA (PO)
  • 24 Nov 2008 ATI 0917 is available for licensing (http://www.arisyn.com)
  • 24 Nov 2008 Phase-I clinical trials for HIV infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top